Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > comparing potential partners?

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Nov 09, 2022 4:08pm

118 Views

Post# 35086438

RE:RE:RE:RE:RE:comparing potential partners?

I do not have access to my computer right now so cannot compare that presentation to any previous one. So just want to confirm with you that you are saying that onc guidance has always been only for bracelet results in the first half of 2023. If that is so then I apologize but will check later and if that is not the case then I would expect the same of you. Thanks again for your posts as many are very informative

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing